The study of Nef mutant clones of human immunodeficiency virus (HIV). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The study of Nef mutant clones of human immunodeficiency virus (HIV).

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:108 (poster no. 67). Unique Identifier : AIDSLINE ASHM5/94348927
Arunagiri CK; Peden K; Azad A; McPhee D; Biomolecular Research Institute, Parkville.

Abstract: A study was initiated to determine the function of Nef auxiliary protein replication of HIV. A molecular clone of HIV, LAI, was selected and two truncated (termination at amino acid 46 and 88) nef mutant clones constructed. The proviral DNA of the mutants and wild type were used to transfect Hela cells. Virus produced in Hela cells was passaged onto primary T4 lymphocytes and virus stocks generated for replication kinetic studies. The cells were infected at different multiplicities of infection (MOI). The results indicate that the nef mutant clones are slower in their ability to replicate at low MOI in both primary cells. However, at MOI of 1, there was no difference in the replication kinetics of wild type and nef mutants. This highlights the different effects of the Nef if different MOI are used. We conclude that the Nef protein is a positive factor at low MOI.
Keywords: *Cloning, Molecular CD4-Positive T-Lymphocytes/MICROBIOLOGY Genes, nef/*GENETICS Hela Cells Human HIV/*GENETICS Mutation/*GENETICS Transfection/GENETICS Virus Replication/GENETICS ABSTRACTKWDcloning,molecularcd4-positivet-lymphocytes/microbiologygenes,nef/KWDgeneticshelacellshumanhiv/KWDgeneticsmutation/KWDgeneticstransfection/geneticsvirusreplication/geneticsabstract
941230
M94C4300

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .